My battle with cancer. Part 1

Area of Science:

• Oncology
• Cancer Therapeutics
• Translational Medicine

Background:

• The patient was diagnosed with numerous brain metastases from lung cancer in January 2023.
• This diagnosis prompted a mission to investigate curative-intent treatments for metastatic cancer.

Purpose of the Study:

• To argue that sequential monotherapy with targeted drugs cannot cure metastatic cancer.
• To propose that preemptive combinations of targeted drugs may theoretically cure metastatic cancer.
• To share personal insights on cancer treatment, including the role of rapamycin.

Main Methods:

• The study presents a theoretical argument based on the author's personal experience and understanding of cancer biology.
• It reviews the limitations of monotherapy and the potential of combination therapies.
• Personal insights on rapamycin's effect on cancer and aging are discussed.

Main Results:

• Sequential targeted drug therapy, even when administered in sequence, is unlikely to achieve a cure for metastatic cancer.
• Preemptive combination therapy with targeted drugs presents a theoretical possibility for curing metastatic cancer.
• Rapamycin, an anti-aging drug, can delay but not prevent cancer progression.

Conclusions:

• Monotherapy approaches are insufficient for curing metastatic lung cancer.
• Combination targeted drug strategies, applied preemptively, hold theoretical promise for curative treatment.
• Further research into combination therapies is warranted to explore curative potential for metastatic cancers.